A Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ (Hydroxypropyl-β-cyclodextrin) and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann-Pick Disease Type C1
Active, not recruitingCTIS2024-518266-27-00
Cyclo Therapeutics Inc.Niemann Pick Disease Type C1
Start: 2022-02-02Target: 36Updated: 2025-11-28